Curidium Medica plc ("Curidium" or "the Company") PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2007 LONDON, UK, 12 May 2008, Curidium Medica plc, (LSE :CUR ), the personalised medicine company focused on bringing the right drug to the right patient, announced today its Preliminary Results for the year ended 31 December 2007. Financial highlights Year ended Year ended 31 December 31 December 2007 2006 Research and Development expenditure GBP389,994 GBP304,712 Group Operating Loss GBP1,292,973 GBP976,558 Group Loss Before Tax GBP1,167,659 GBP945,036 Loss per Share 0.20p 0.24p Cash out flow from operating activities GBP1,276,104 GBP627,291 Operational highlights * Signed partnership agreement with Takeda Research Investment Inc. applying Homomatrix® to Major Depressive Disorder * Raised GBP2.5 million in subscription agreement * Trademarked "PsychINDx" as blood test for Schizophrenia (SZ) / Bipolar (BP) Disorder patient subgroups * Discovered statistically significantly different patient subgroups in SZ/BP Disorder * Discovered unique Gene Expression Profiles in blood of SZ/BP patient subgroups Gosse Bruinsma, Executive Chairman of Curidium said:"This has been a transformational year for Curidium in which its proprietary technology Homomatrix® consecutively proved to identify the statistically significant patient sub-groups, thereby proving the technology strategy, the Balance Sheet was strengthened with a significant fund raising in July 2007 and we signed a strategic research alliance with Takeda Research which included a GBP1.25m investment."In 2008 overall market conditions are encouraging with both regulatory and 'pharmaco-economics' driving interest in effective personalised medicine solutions. We have stepped up our marketing of PsychINDxTM to a number of preferred partners and have received a favourable reception to date. We continue to believe and drive towards our overriding company objective: to bring theright drug to the right patient." Click on the following link or paste into your browser to view the full announcement: http://www.rns-pdf.londonstockexchange.com/rns/4090U_1-2008-5-14.pdf - Ends - For further information please contact: Gosse B. Bruinsma, M.D. +31 (0) 629 046 397 Executive Chairman, Curidium Medica plc Rob Smith +44 (0) 20 7383 5345 Finance Director, Curidium Medica plc Charlie Cunningham +44 (0) 20 7600 1658 FinnCap Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113 Financial Dynamics This information is provided by RNS The company news service from the London Stock Exchange END
Contact Information: For further information please contact: Gosse B. Bruinsma M.D. +31 (0) 629 046 397 Executive Chairman Curidium Medica plc Rob Smith +44 (0) 20 7383 5345 Finance Director Curidium Medica plc Charlie Cunningham +44 (0) 20 7600 1658 FinnCap Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113 Financial Dynamics